Market News
Monday, January 23, 2017
BRIEF-Aptose prioritizes development of CG'806 first-in class FLT3/BTK Inhibitor
* Will prioritize resources toward development of CG'806 for
patients with FLT3-driven acute myeloid leukemia (AML)
Read more
No comments:
Post a Comment
Newer Post
Older Post
Home
Subscribe to:
Post Comments (Atom)
No comments:
Post a Comment